Study confirms benefit of regorafenib in previously treated metastatic colorectal cancer

the ONA take:

According to research presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have confirmed that regorafenib is beneficial for the treatment of patients with previously treated metastatic colorectal cancer.

The phase III CORRECT study previously demonstrated a significant improvement in progression-free survival in patients with previously treated metastatic colorectal cancer. For the phase IIIb CONSIGN trial, researchers prospectively assessed the efficacy and safety of regorafenib in patients with pre-treated metastatic colorectal cancer before marketing of the drug was authorized.

The study showed that the estimated progression-free survival was 2.7 months and there were no surprising findings in regard to adverse events.

The CONSIGN trial is significant in that its patient population more closely resembled a real world population of patients compared with the CORRECT trial

"CONSIGN confirms the efficacy and safety data of the randomised phase III CORRECT and CONCUR trials. The merit of CONSIGN is that it translates phase III data into the clinical routine since patients had similar characteristics and pre-treatment to what we see in daily practice," Dirk Arnold, MD, ESMO spokesperson, director of the Department of Medical Oncology, Klinik für Tumorbiologie in Freiburg, Germany, said.

Trastuzumab improves survival for HER2-positive breast cancer
Researchers have confirmed that regorafenib is beneficial for the treatment of previously treated metastatic colorectal cancer.
The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs